Skip to content

Exploring conformational dynamics of the HER2 DFG-flip using machine-learning-guided metadynamics for type II inhibitor design.

Aug 2026 · Computational biology and chemistry · Vol 125, pp. 109315 · 0 citations · 79 references
Medicine

TL;DR

Together, these results provide a structurally grounded inactive-state HER2 model and a mechanistic framework for structure-based design of HER2 inhibitors targeting inactive kinase conformations, highlighting the applicability of deep learning CVs to systems of complex free energy landscape.

Abstract

Protein kinases regulate cellular proliferation and survival through tightly controlled signalling mechanisms, and their dysregulation is a major driver of cancer. Human epidermal growth factor receptor 2 (HER2) is a clinically validated kinase target, yet structural and drug-discovery efforts have largely focused on type I inhibitors binding the active DFG-in conformation. The absence of experimentally resolved structures for HER2 in the inactive DFG-out state has limited structure-based development of inactive-state type II inhibitors. Here, we employ molecular dynamics (MD) simulations coupled with machine-learning-guided well-tempered metadynamics (MetaD) to characterize the conformational landscape underlying the DFG-in to DFG-out transition in HER2. Deep learning-based collective variable was constructed by the Deep Targeted Discriminant Analysis (DeepTDA) method employing unbiased MD data from both metastable states. DeepTDA enabled efficient sampling of the DFG-flip pathway, capturing multiple recrossing events and allowing reliable estimation of the free energy difference between the two states within accessible simulation time. The inactive DFG-out conformation is found to be energetically favoured by approximately 25 kJ/mol relative to the DFG-in state, in close agreement with experimental and computational data from other apo kinases. In addition to the canonical active conformation observed crystallographically, we identify an alternative DFG-in conformer that may contribute to the low intrinsic kinase activity reported for HER2. A DFG-up intermediate conformer is also observed, resembling crystal structures reported for Aurora-A kinase. A combined covalent docking and molecular dynamics approach followed to assess the MetaD-predicted DFG-out structure for ligand binding reliability, yielding comparable predicted/experimental binding affinity. Together, these results provide a structurally grounded inactive-state HER2 model and a mechanistic framework for structure-based design of HER2 inhibitors targeting inactive kinase conformations, highlighting the applicability of deep learning CVs to systems of complex free energy landscape.

View source

Similar papers

Aug 2026

Targeting WEE1 kinase: an integrated machine learning–cheminformatics framework for ultra-large-scale virtual screening and novel inhibitor discovery

A scalable, machine-learning-integrated virtual screening framework designed to explore ultra-large chemical space spanning an input search space of approximately 884 million compounds from ZINC20 and 199,854 purchasable compounds from the SPECS database is reported.

R. Muthuraj, Manasa Pacharla, Nehal Arvind Kumar et al. · 0 citations
Open access Aug 2026

From Descriptor Learning to Binding Stability: An Explainable Machine Learning Pipeline for EGFR Double-Mutant Inhibitor Discovery

An integrated computational workflow combining explainable machine learning, virtual screening, molecular dynamics simulations, and binding free-energy calculations to identify novel inhibitors of this drug-resistant EGFR variant may support the development of new therapeutic strategies for overcoming resistance in EGFR-driven cancers.

Jurica Novak · 0 citations
Open access Aug 2026

Targeting BCL‑2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation

A multimodal BCL-2 repurposing workflow built with diffusion-based generative modeling for ligand-specific complex generation and an extended neural relational inference (NRI) framework for trajectory-level interaction analysis is presented, establishing a strategy that couples generative complex prediction with graph-based dynamic inference for structure-guided drug repurposing.

Ehsan Sayyah, H. Tunc, A. Çelebi et al. · 0 citations
Aug 2026

Decoding MLK4 Inhibition with Interpretable Machine Learning: Identification of a Novel Dihydroimidazopyridine-Based Promising Lead Compound

These findings introduce H_1 as a computationally prioritized, putative MLK4-binding lead and provide a hypothesis-generating framework for MLK4-targeted scaffold prioritization, while recognizing that experimental activity and kinome selectivity profiling remain necessary before H_1 can be described as a confirmed MLK4 inhibitor or MLK4-selective compound.

Afnan A. Alzaghari, S. Daoud, Husam Nassar et al. · 0 citations
Open access Aug 2026

Integrating molecular dynamics and machine learning to identify potential apo-state conformational and solvent-exposure signatures associated with resistant KRAS mutants

A computational framework integrating molecular dynamics (MD)-derived structural, energetic, thermodynamic, and contact-based descriptors with machine learning may inform the design of inhibitors targeting secondary KRAS resistance mutations, pending validation in additional structurally independent mutant systems.

Katarzyna Mizgalska, Konstancja Urbaniak, Denis Imbody et al. · 0 citations
#graph neural networks Open access Aug 2026

Discovery of a potent TDP1 inhibitor through machine learning-driven predictive modeling combined with structure-based virtual screening and experimental validation

An integrated computational framework combining machine learning (ML), deep learning (DL), and structure-based docking with experimental validation identifies AO65 as a promising lead for further TDP1-focused investigation.

Huang Zeng, Man-Yi Zhang, Bo Qiu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.